Compare · ARGX vs DNA
ARGX vs DNA
Side-by-side comparison of argenx SE (ARGX) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and DNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.83B, about 120.9x DNA ($436.9M).
- Over the past year, ARGX is up 30.2% and DNA is down 48.4% - ARGX leads by 78.6 points.
- ARGX has been more active in the news (13 items in the past 4 weeks vs 8 for DNA).
- ARGX has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- argenx SE
- Ginkgo Bioworks Holdings Inc.
- Price
- $851.51-0.63%
- $6.78-6.16%
- Market cap
- $52.83B
- $436.9M
- 1M return
- -0.84%
- -18.21%
- 1Y return
- +30.17%
- -48.44%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- 2021
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 18
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest ARGX
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
- argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
- SEC Form SC TO-C filed by argenx SE
- SEC Form SC TO-C filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
Latest DNA
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Canton Barry
- SEC Form 4 filed by Officer Shetty Reshma P.
- SEC Form 4 filed by Officer Kelly Jason R
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Coen Steven P. converted options into 1,486 shares and sold $5,943 worth of shares (752 units at $7.90), increasing direct ownership by 1% to 51,438 units (SEC Form 4) (tax liability)
- SEC Form 4 filed by Director Henry Christian O
- SEC Form 4 filed by Director Fubini Ross